CN1066959C - Medicine for treating hydrocephalus - Google Patents
Medicine for treating hydrocephalus Download PDFInfo
- Publication number
- CN1066959C CN1066959C CN98113028A CN98113028A CN1066959C CN 1066959 C CN1066959 C CN 1066959C CN 98113028 A CN98113028 A CN 98113028A CN 98113028 A CN98113028 A CN 98113028A CN 1066959 C CN1066959 C CN 1066959C
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- present
- rhizoma
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating hydrocephalus, which takes traditional Chinese medicines, such as bezoar, borneol, chuanxiong rhizome, angelica, grassleaf sweetflag rhizome, gastrodia tuber, centipede, earthworm, indian bread exodermis and safflower as raw materials. The raw materials are prepared into medicinal powder, or capsules, or tablets according to a common preparation method. Pharmacodynamics tests prove that the medicine of the present invention has the efficiency of improving a quantity of nervous system clinical symptoms of hydrocephalus, reducing existence of cerebrospinal liquid, and reducing the increase of intracranial pressure. 126 primary clinical observation test results indicate that the medicine of the present invention has the advantages of no toxic or side effect and conspicuous curative effect, and the total effective rate is 91.27%. After the medicine of the present invention further extends clinical tests, the medicine of the present invention can be clinically popularized.
Description
The invention belongs to the medicinal preparation technical field of the product that contains raw material or fuzzy structure, being specifically related to a kind of is the hydrocephalic Chinese patent medicine of treatment that raw material is made with botanical herbs and nonmammalian.
The hydrocephalus disease is at the sickness rate height of China, domestic statistics shows, only the sickness rate of neonate congenital hydrocephalus is up to 6.64～11.84 people/ten thousand people, and become ascendant trend year by year, annual domestic 360,000 examples that increase newly at least, newly-increased approximately 1,500,000 examples in the whole world seriously influence human beings'health, and patient, family and society have all been caused great harm.
Treat hydrocephalic medicine and belong to the exploratory development stage in the world, Japan attempts with hydrocephalus behind " fibrinolytic therapy " treatment intracranial hemorrhage, and it is studied still in animal experiment stage, and Russia and some English-speaking countries still do not have conclusion with methylphenidate treatment hydrocephalus.The treatment hydrocephalus adopts oral Acetazolamide both at home and abroad, by suppressing the carbonic anhydrase activity, suppresses the generation of choroid plexus to cerebrospinal fluid, and curative effect is very little.Treatment hydrocephalus disease, the present domestic Chinese patent medicine that still do not have.
The objective of the invention is to have no side effect for the hydrocephalus disease provides a kind of, the significant Chinese patent medicine of therapeutic effect.
For achieving the above object, it is the Chinese patent medicine of making than (consumption is a weight portion) with following set of dispense for the solution that the present invention adopts:
1.2～4 parts of 2～4 parts of Borneolum Syntheticums of Calculus Bovis
16～20 parts of 16～20 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
8～12 parts in 16～20 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
8～12 parts of 2～6 parts of Pheretimas of Scolopendra
10～14 parts on 16～20 parts of Flos Carthamis of Cortex Sclerotii Poriae
The proportion optimization weight ratio scope of preparation medicine of the present invention is:
1.5～3 parts of 2～3 parts of Borneolum Syntheticums of Calculus Bovis
18～20 parts of 16～18 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
8～10 parts in 18～20 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
8～10 parts of 3～5 parts of Pheretimas of Scolopendra
10～12 parts on 16～20 parts of Flos Carthamis of Cortex Sclerotii Poriae
The optimum weight proportioning of preparation medicine of the present invention is:
1.8 parts of 3 parts of Borneolum Syntheticums of Calculus Bovis
18 parts of 18 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
9 parts in 18 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
9 parts of 3 parts of Pheretimas of Scolopendra
12 parts on 18 parts of Flos Carthamis of Cortex Sclerotii Poriae
The medicament that above-mentioned each component is made according to a conventional method is said powder or capsule or a tablet on the galenic pharmacy, also can be made into oral liquid.
The preparation technology of drug powder of the present invention is as follows:
1. get raw material, choose decontamination and the part of going mouldy, its quality is checked, weigh by proportioning by Chinese Pharmacopoeia.
2. get Radix Angelicae Sinensis, Rhizoma Chuanxiong, that Rhizoma Acori Graminei is ground into 100 order fineness is standby.
3. get Calculus Bovis and grind to form 100 order fine powders.
4. Flos Carthami, Pheretima, Cortex Sclerotii Poriae, Rhizoma Gastrodiae, Scolopendra are ground into coarse powder, decoct with water, the decocting that adds 8～10 times of amounts for the first time boiled 2 hours, the decocting that adds for the second time 4～6 times of amounts boiled 1.5 hours, merged decocting liquid twice, filtered, discard residue, it is 1.30 extractum that filtrate decompression is concentrated into proportion.
5. get Borneolum Syntheticum, till adding medical ethanol to Borneolum Syntheticum dissolves, make the Borneolum Syntheticum alcoholic solution.
6. above-mentioned 2 obtained fine powders are joined in the extractum; fully mix; 60 ℃ of oven dry; be ground into 100 order fine powders, add the Calculus Bovis fine powder, spray into the Borneolum Syntheticum alcoholic solution; add starch excipient and small amount of moisture again and to every gram drug powder of the present invention, contain crude drug 1.26g; fully mix, 50 ℃ of dryings are ground into 100 order fineness.
7. by the quality standard check of drug powder of the present invention, every gram drug powder of the present invention contains crude drug 1.26g, in the plastic bag of behind ultraviolet disinfection, packing into, and every bag heavy 0.5g.
The preparation technology of medicine capsule of the present invention is as follows:
1. pre-treatment of raw material is identical with the preparation technology 1 of drug powder of the present invention.
2. get Rhizoma Chuanxiong, Rhizoma Acori Graminei is ground into coarse powder, decoction alcohol precipitation method extracts, and reclaims ethanol, concentrating under reduced pressure becomes concentrated solution.
3. get Radix Angelicae Sinensis, Pheretima, that Cortex Sclerotii Poriae is ground into 100 order fine powders is standby.
4. get Rhizoma Gastrodiae, Scolopendra, Flos Carthami powder and be broken into coarse powder and decoct with water twice, add 8～10 times of water gagings for the first time and decocted 2 hours, add 4～6 times of water gagings for the second time and decocted 1.5 hours, filter, merging filtrate is evaporated to proportion and is 1.30 extractum.
5. concentrated solution and extractum are mixed the fine powder that adds 3 preparations, 60 ℃ of oven dry are ground into 100 order fine powders.
6. with 5 fine powder and the Calculus Bovis facing-up mixings that prepare.
7. get Borneolum Syntheticum, add medical ethanol, make the Borneolum Syntheticum alcoholic solution to all dissolvings, spray into the fine powder of 6 preparations, add starch excipient and small amount of moisture again, to every gram medicine capsule of the present invention, contain crude drug in whole 1.576g, fully mix, 50 ℃ of dryings are ground into 100 order fineness.
8. by the quality standard check of medicine capsule of the present invention, every gram medicine capsule of the present invention contains crude drug 1.576 grams, in incapsulating behind ultraviolet disinfection, promptly makes medicine capsule of the present invention, every heavy 0.5 gram.Proportioning raw materials that capsule is used and preparation technology press capsule proportioning raw materials preparation technology's making routinely on the galenic pharmacy.
The preparation technology of medicinal tablet of the present invention is as follows:
The proportioning of the proportioning of the used raw material of Chinese medicine of medicinal tablet of the present invention and the extraction of active ingredient and the used raw material of Chinese medicine of medicine capsule of the present invention and the extraction of active ingredient are identical, and the adjuvant that used adjuvant and consumption are pressed among the conventional preparation technology of tablet is selected.The preparation technology of medicinal tablet of the present invention is undertaken by the conventional preparation technology of tablet on the galenic pharmacy.Every heavy 0.3 gram, every gram contains crude drug in whole 1.576 grams.
Medicine of the present invention proves that through pharmacodynamics test medicine of the present invention helps to improve some nervous system clinical symptoms that hydrocephalus occurs, and helps to reduce cerebrospinal fluid and generates, and minimizing produces excessive by cerebrospinal fluid and causes that intracranial pressure raises.Medicine of the present invention is through the routine Preliminary Clinical Observation test of treatment hydrocephalus 126, and the result shows that medicine of the present invention has and have no side effect that evident in efficacy, total effective rate is 91.27%, can further promote the use of clinically after the expanding test clinically.
For showing medicine of the present invention to hydrocephalic therapeutic effect, applicant consignment test unit has carried out pharmacodynamics and Preliminary Clinical Observation test to medicine of the present invention (name is called brain Kang Ling during test), and test situation is as follows:
One, pharmacodynamics test
Be subjected to the reagent thing: medicine of the present invention is prepared into 167% decocting liquid.
Laboratory animal: ICR strain mice, SD strain rat, white rabbit.
1. medicine of the present invention is to the influence of mice autonomic activities
Test method: 64 of mices, body weight 21.1 ± 1.0g, the male and female dual-purpose is divided into four groups at random, every group 16, promptly tap water matched group (20ml/kg), medicine of the present invention heavy dose are organized dosage group (15g/kg), medicine small dose group of the present invention (7.5g/kg) in (30g/kg), the medicine of the present invention.Gastric infusion, once a day, continuous 10 days, after the last administration 40 minutes, per 2 mices were after a group puts into mice autonomic activities monitor and adapts to 5 minutes, write down the movable number of times of mice in 10 minutes, t checks and organizes a statistical procedures.
Experimental result: drug study group of the present invention is not seen obvious influence to the free movable number of times of mice.
2. medicine of the present invention is to the active influence in mice wilderness
Test method: 68 of mices, body weight 21.3 ± 1.2g, the male and female dual-purpose is divided into four groups at random, every group 17, promptly tap water matched group (20ml/kg), medicine of the present invention heavy dose are organized dosage group (15g/kg), medicine small dose group of the present invention (7.5g/kg) in (30g/kg), the medicine of the present invention.Gastric infusion, once a day, continuous 10 days, after the last administration 40 minutes, per 2 mices were by only putting into the wilderness case, and the record mice enters behind the case of wilderness active lattice number in 2 minutes, and a statistical procedures is organized in the t check.
The wilderness case is the no top boxs of 100 * 100 * 40 (cm), and the bottom is divided into 36 and waits lattice, experimentizes when 150W bulb of case top about 100cm place extension, bright lamp, and mice extremity are gone to the same lattice lattice of having walked about.
Result of the test: medicine of the present invention all can significantly increase by three active number of times in experimental mice wilderness (p＜0.05 or p＜0.01).Compare * p＜0.05, * * p＜0.01 with matched group.
3.1 medicine of the present invention is to the influence-diving tower method of memory defects model mice
Test method: 102 of mices, body weight 22.8 ± 1.0g, the male and female dual-purpose, be divided into six groups at random, be tap water matched group (20ml/kg), moulding group (hyoscine hydrobromate 2mg/kg), dosage group (15g/kg), medicine small dose group of the present invention (7.5g/kg) in positive drug piracetam matched group (2.4g/kg), the heavy dose of group of medicine of the present invention (30g/kg), the medicine of the present invention.Each organize every day gastric infusion once, continuous 10 days, after the administration in the 10th day 45 minutes, mice is put into the passive avoidance reflective box, adapt to 3 minutes, training earlier, energising, when mice is subjected to shocking by electricity, its normal reaction is the rebound diving tower to hide electric shock, and the mice biped contacts the copper grid simultaneously for getting an electric shock, and is considered as wrong reaction, trained 5 minutes, and write down errors number in 5 minutes.Its memory state is observed in test again after 24 hours, and after the administration 35 minutes, except that first group of control mice, the abdominal cavity is given and scopolamine 2mg/kg, and mice is put into reflective box, energising, the record mice jumps onto the diving tower time for the first time, is considered as incubation period, and writes down errors number in 5 minutes.A statistical procedures is organized in the t check.
The passive avoidance reflective box, it is 24 * 12 * 28cm chamber, be divided into two with light tight cardboard in the case, the shop is with the copper grid at the bottom of the case, brass wire diameter is 2mm, and spacing is 5mm, and current intensity passes to the 36V electric current by transformator control, a high valve rubber that is 4.5cm with diameter is placed as diving tower in every right back, and this is the place of safety that mice is avoided electric shock.
Result of the test: medicine 15g/kg of the present invention can make that errors number obviously reduces (p＜0.05) in the memory defects mice 5 minutes, and certain shortening tendency (p＞0.05) is also arranged simultaneously incubation period.Experimental group and matched group be Δ p＜0.05 relatively, and experimental group and moulding group be * p＜0.05 relatively.
3.2 medicine of the present invention is to the influence-Y type water maze method of memory defects model mice
Test method: 90 of mices, body weight 19.9 ± 1.3g, the male and female dual-purpose, be divided into six groups at random, every group 15, be tap water matched group (20ml/kg), moulding group (scopolamine 2mg/kg, ip), dosage group (15g/kg) in the positive drug piracetam group (2.4g/kg), the heavy dose of group of medicine of the present invention (30g/kg), medicine of the present invention, medicine small dose group of the present invention (7.5g/kg).Gastric infusion, once a day, continuous 10 days, rise the 6th day of administration, the mice administration is placed on the lost case swimming of Y type water, writes down every mice and arrives at the platform required time, trains secondary every day, continuous 4 days.Administration the 10th day, after the last administration 35 minutes, except that matched group, every group of mouse peritoneal injection scopolamine 2mg/kg, mice is put the lost case swimming of Y type water again after 10 minutes, writes down every mice and arrives at the platform required time.A statistical procedures is organized in the t check.
Result of the test: normal mouse training in 4 days, arriving at the platform required time has shortening trend (p＞0.05), administration the 10th day, behind the lumbar injection scopolamine, arrives at the platform required time and prolongs.It is not obvious that experimental mice arrives at the influence of platform required time.
4. medicine of the present invention causes the influence of convulsions mice to pentetrazole
Test method: 75 of mices, body weight 20.4 ± 1.2g, the male and female dual-purpose, be divided into five groups at random, every group 15, promptly tap water matched group (20ml/kg), piracetam group (2.4g/kg), medicine of the present invention heavy dose are organized dosage group (15g/kg), medicine small dose group of the present invention (7.5g/kg) in (30g/kg), the medicine of the present invention.Gastric infusion, once a day, continuous 10 days.After the last administration 40 minutes, every mouse peritoneal injection pentetrazole 100mg/kg write down every mice takes place the incubation period that paroxysmal is fainted from fear, and t check carrying out statistics compares, and writes down the number of animals of every group of mice against seizure simultaneously, X
2Statistical procedures is carried out in check.
Result of the test: but take place the incubation period that paroxysmal is fainted from fear in the equal significant prolongation mice of medicine 30g/kg of the present invention and 15g/kg, and medicine 30g/kg of the present invention also can significantly reduce the number of mice that convulsions takes place simultaneously.Experimental group and matched group be * p＜0.05 relatively.
5. medicine of the present invention is to the influence of mouse peritoneal capillary permeability
Test method: 90 of mices, body weight 22.1 ± 0.9g, the male and female dual-purpose, be divided into five groups at random, every group 18, be tap water matched group (20ml/kg), dosage group (15g/kg), medicine small dose group of the present invention (7.5g/kg) in positive drug aspirin group (200mg/kg), the heavy dose of group of medicine of the present invention (30g/kg), the medicine of the present invention.Gastric infusion, once a day, continuous 10 days, after the last administration 30 minutes, tail vein injection 0.5% Yi Wensilan solution (5ml/kg), lumbar injection 0.7% glacial acetic acid normal saline (10ml/kg), put to death mice after 15 minutes, with normal saline 10ml flushing abdominal cavity, flushing liquor is got liquid photometry density after centrifugal, and relatively the abdominal cavity capillary permeability changes.
Result of the test: medicine of the present invention can obviously suppress the permeability (p＜0.01) of mouse peritoneal blood capillary.Experimental group and matched group compare, * p＜0.05, * * p＜0.01.
6. medicine of the present invention is to the influence of rabbit intracranial pressure
Test method: healthy white rabbit, body weight 2.0～2.5kg, male and female dual-purpose, with the anesthesia of 10% urethane intravenously administrable, remake the ventriculus sinister cerebri intubate during experiment, the intubate position is at left coronal suture, the other 4mm of center line bores aperture, inserts vinyl tube to tricorn, fixedly intubate.The other end of plastic tube links to each other with RM-6000 polygraph (Japanese photoelectricity company) by pressure transducer, trace tricorn pressure, after treating pressure stability, duodenum is given medicine of the present invention, observes the drug-induced rabbit tricorn of the present invention internal pressure and changes.A statistical procedures is organized in the t check.
Result of the test: medicine 10g/kg of the present invention can obviously reduce rabbit tricorn pressure (p＜0.05), and can keep about 20 minutes, and experimental group and matched group compare, * p＜0.05, * * p＜0.01.
7. medicine of the present invention is to the influence of rat urine amount
Test method: 50 of rats, body weight 198.0 ± 13.6g, male and female half and half, be divided into five groups at random, every group 10, promptly tap water matched group (20ml/kg), positive drug acetazolamide group (10mg/kg), medicine of the present invention heavy dose are organized dosage group (15g/kg), medicine small dose group of the present invention (7.5g/kg) in (30g/kg), the medicine of the present invention.Gastric infusion, once a day, continuous 10 days, administration the 10th day, first physiology saline load secondary, 1 hour at interval, each stomach of irritating is given normal saline 25ml/kg, gives for the second time with normal saline and gives and medicine of the present invention simultaneously, places rat in the metabolic cage respectively then, per hour write down each rat urine amount, continuous record 6 hours.Statistical procedures is carried out in the t check.
Result of the test: medicine 7.5g/kg of the present invention obviously increases rat urine amount (p＜0.05 or p＜0.01), 15g/kg then after administration 6 hours urine amounts obviously increase (p＜0.05), 30g/kg does not have obvious influence to the urine amount.Experimental group and matched group compare, * p＜0.05, * * p＜0.01.
8. medicine of the present invention is to carbonic anhydrase activity influence in the rat cerebral tissue
Test method: rat, grouping is with experiment (7).Every day gastric infusion once, continuous 10 days, after the last administration 1 hour, the sacrificed by exsanguination rat was taken out full brain rapidly, clean blood with cold distilled water, the filter paper suck dry moisture claims full cutaneous horn heavy, cuts cerebral tissue at same position, accurately take by weighing 200mg and put into dismembyator, add the 8ml cold distilled water simultaneously, grind to form homogenate in frozen water, homogenate places in vitro, with under the 1500rpm speed centrifugal 20 minutes, draw supernatant 5ml, add quantitative 0.1% bromothymol blue solution, the constant voltage constant speed feeds carbon dioxide, observe solution and change into yellow required time, relatively the activity of carbonic anhydrase in the cerebral tissue by blue color.A statistical procedures is organized in the t check.
Result of the test: medicine 7.5g/kg of the present invention has the tendency (p＜0.01) that reduces carbonic anhydrase in the cerebral tissue.Experimental group and matched group compare, * * p＜0.01.
Help to improve the clinical card shape of some nervous system that hydrocephalus occurs from the result of the test proof medicine of the present invention of above pharmacodynamics test 2～4.Help to reduce the cerebrospinal fluid generation from the result of the test proof medicine of the present invention of pharmacodynamics test 5～8, reduce producing excessive and intracranial pressure rising that cause by cerebrospinal fluid, diuresis then helps to reduce the intracranial pressure that has raise.This conclusion provides certain experiment basis to Drug therapy hydrocephalus of the present invention.
Two, Preliminary Clinical Observation test
1. diagnostic criteria: 1. body is grown disproportionate or head circumference surpasses 2 standard deviations or scalp vein anger rises: 2. fontanel enlarges, and exceeding the time limit does not conform to, nervous full or sutura cranii division, head percussion audible and macEven's sign; 3. eyeball backspin such as setting sun shape, or tremble, or stravismus; 4. mentally disabled; 5. retardation of speaking, or Motor development is unusual, vomiting or tic, and the tinnitus ear blocks up and is difficult to other disease exponent; 6. iconography (CT, MRT, the X line) person that check to confirm there is the hydrocephalus.
All have 1. above～one of 5. and 6. person, and diagnosable is hydrocephalus.
2. clinical data: be diagnosed as hydrocephalic's 126 examples by the diagnosis standard, wherein male 72 examples, women 54 examples, the oldest 65 years old, minimum 4 months, out-patient treatment 64 examples, hospitalization 62 examples.Through CT examination, traffic 47 examples, infraction property 79 examples.Clinical symptoms performance is show effect 28 examples, vomiting 35 examples, limb adynamia 87 examples, asymptomatic person 22 examples of big person's 108 examples of head, setting sun order 62 examples, headache 68 examples, epileptic obviously.Complication: brain atrophy 27 examples, arachnoid cyst 9 examples, nasopharynx tuberculation 6 examples, astrocytoma 2 examples, glioma 19 examples, neuroblastoma 2 examples.Maternal infuries history 69 examples, trauma history 4 examples arranged, change brain history 29 examples, knot brain history 23 examples, pregnancy period are generated heat 33 examples, the pregnancy period is taken medicine history 18 examples.
3. trial drug: medicine capsule of the present invention, every heavy 0.5 gram, every gram crude drug content 1.576 grams.
4. Therapeutic Method: every day three times, ante cibum is oral, and one month is a course of treatment, treats three courses of treatment.
Using dosage: below 2 years old each 2,2～3 years old each 3,3～7 years old each 4, more than 7 years old each 5.
5. efficacy assessment standard
Recovery from illness: clinical symptom disappearance, image check Non Apparent Abnormality; Produce effects: clinical symptoms obviously alleviates, and image check hydrops reduces; Effectively: clinical symptom relief, image check hydrops does not have increase; Invalid: clinical symptoms does not have and is clearly better.
6. therapeutic outcome: after three course of therapy, test shows that by statistics 59 examples of fully recovering account for 46.83%, and produce effects 39 examples account for 30.95%, and effective 17 examples account for 13.49%, and invalid 11 examples account for 8.73%, and total effective rate is 91.27%.
The inventor has provided used raw material and the proportioning thereof of first embodiment of the invention (is example for 100 kilograms with production powder product of the present invention):
Calculus Bovis 2.65kg
Borneolum Syntheticum 1.59kg
Rhizoma Chuanxiong 21.18kg
Radix Angelicae Sinensis 21.18kg
Rhizoma Acori Graminei 21.18kg
Rhizoma Gastrodiae 10.59kg
Scolopendra 2.65kg
Pheretima 10.59kg
Cortex Sclerotii Poriae 21.18kg
Flos Carthami 13.21kg
Starch adds to 100kg
The inventor has provided used raw material and the proportioning thereof of first embodiment of the invention (is example for 100 kilograms with production capsule product of the present invention):
Calculus Bovis 3.31kg
Borneolum Syntheticum 2kg
Rhizoma Chuanxiong 26.49kg
Radix Angelicae Sinensis 26.49kg
Rhizoma Acori Graminei 26.49kg
Rhizoma Gastrodiae 13.24kg
Scolopendra 3.31kg
Pheretima 13.24kg
Cortex Sclerotii Poriae 26.49kg
Flos Carthami 16.54kg
Starch adds to 100kg
In its proportioning, the weight portion of each component of raw material of Chinese medicine is:
1.2 parts of 2 parts of Borneolum Syntheticums of Calculus Bovis
16 parts of 16 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
8 parts in 16 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
8 parts of 2 parts of Pheretimas of Scolopendra
10 parts on 16 parts of Flos Carthamis of Cortex Sclerotii Poriae
It is example that the inventor has provided second embodiment of the invention (with 100 kilograms of production powder products of the present invention)) used raw material and proportioning thereof be:
Calculus Bovis 3.82kg
Borneolum Syntheticum 3.82kg
Rhizoma Chuanxiong 19.09kg
Radix Angelicae Sinensis 19.09kg
Rhizoma Acori Graminei 19.09kg
Rhizoma Gastrodiae 11.45kg
Scolopendra 5.73kg
Pheretima 11.45kg
Cortex Sclerotii Poriae 19.09kg
Flos Carthami 13.77kg
Starch adds to 100kg
The inventor has provided used raw material and the proportioning thereof of second embodiment of the invention (is example for 100 kilograms with production capsule product of the present invention):
Calculus Bovis 4.78kg
Borneolum Syntheticum 4.78kg
Rhizoma Chuanxiong 23.88kg
Radix Angelicae Sinensis 23.88kg
Rhizoma Acori Graminei 23.88kg
Rhizoma Gastrodiae 14.33kg
Scolopendra 7.16kg
Pheretima 14.33kg
Cortex Sclerotii Poriae 23.88kg
Flos Carthami 16.70kg
Starch adds to 100kg
In its proportioning, the weight portion of each component of raw material of Chinese medicine is:
4 parts of 4 parts of Borneolum Syntheticums of Calculus Bovis
20 parts of 20 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
12 parts in 20 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
12 parts of 6 parts of Pheretimas of Scolopendra
14 parts on 20 parts of Flos Carthamis of Cortex Sclerotii Poriae
The inventor has provided used raw material and the proportioning thereof of third embodiment of the invention (is example for 100 kilograms with production powder product of the present invention):
Calculus Bovis 3.44kg
Borneolum Syntheticum 2.07kg
Rhizoma Chuanxiong 20.66kg
Radix Angelicae Sinensis 20.66kg
Rhizoma Acori Graminei 20.66kg
Rhizoma Gastrodiae 10.33kg
Scolopendra 3.44kg
Pheretima 10.33kg
Cortex Sclerotii Poriae 20.66kg
Flos Carthami 3.75kg
Starch adds to 100kg
The inventor has provided used raw material and the proportioning thereof of third embodiment of the invention (is example for 100 kilograms with production capsule product of the present invention):
Calculus Bovis 4.31kg
Borneolum Syntheticum 2.58kg
Rhizoma Chuanxiong 25.84kg
Radix Angelicae Sinensis 25.84kg
Rhizoma Acori Graminei 25.84kg
Rhizoma Gastrodiae 12.92kg
Scolopendra 4.31kg
Pheretima 12.92kg
Cortex Sclerotii Poriae 25.84kg
Flos Carthami 17.20kg
Starch adds to 100kg
In its proportioning, the weight portion of each component of raw material of Chinese medicine is:
1.8 parts of 3 parts of Borneolum Syntheticums of Calculus Bovis
18 parts of 18 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
9 parts in 18 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
9 parts of 3 parts of Pheretimas of Scolopendra
12 parts on 18 parts of Flos Carthamis of Cortex Sclerotii Poriae
More than provide the proportioning embodiment of the used raw material of Chinese medicine of medicine capsule of the present invention, the proportioning of the used raw material of Chinese medicine of same applicable preparation identical weight medicinal tablet of the present invention, prepare the selection of the used adjuvant of medicinal tablet of the present invention and the proportioning and the preparation technology of adjuvant, the preparation technology of preparation method tablet carries out routinely.
Function of the present invention: eliminate phlegm for resuscitation, blood circulation promoting and blood stasis dispelling, logical end, kidney tonifying, essence replenishing, invigorating spleen for diuresis relieve dizziness, high fever, infantile convulsions, epilepsy, etc.
The present invention cures mainly: hydrocephalus.
Specification of the present invention: the every bag of drug powder of the present invention weighs 0.5 gram, and every gram contains crude drug in whole 1.26 grams; Every heavy 0.5 gram of medicine capsule of the present invention, every gram contains crude drug in whole 1.576 grams; Every heavy 0.3 gram of medicinal tablet of the present invention, every gram contains crude drug in whole 1.576 grams.
Usage and dosage of the present invention: three times on the one; ante cibum is oral; 8 in the each clothes of adult powder 5 bags or 5 of capsules or tablet; obeyed 7 in powder 4 bags or 4 of capsules or tablet in 3～7 years old at every turn; 5 in 2～3 years old each clothes powder 3 bags or 3 of capsules or tablet, 3 in each clothes powder 2 bags or 2 of capsules or tablet below 2 years old.
Storage of the present invention: the shady and cool dry place storage of sealing.
Effect duration of the present invention: 2 years.
Claims (4)
1. hydrocephalic Chinese patent medicine of treatment is characterized in that it is by the following weight proportion raw material medicament of formulation method preparation routinely:
1.2～4 parts of 2～4 parts of Borneolum Syntheticums of Calculus Bovis
16～20 parts of 16～20 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
8～12 parts in 16～20 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
8～12 parts of 2～6 parts of Pheretimas of Scolopendra
10～14 parts on 16～20 parts of Flos Carthamis of Cortex Sclerotii Poriae
2. according to the hydrocephalic Chinese patent medicine of the described treatment of claim 1, wherein the weight proportion of each raw material is:
1.5～3 parts of 2～3 parts of Borneolum Syntheticums of Calculus Bovis
18～20 parts of 16～18 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
8～10 parts in 18～20 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
8～10 parts of 3～5 parts of Pheretimas of Scolopendra
10～12 parts on 16～20 parts of Flos Carthamis of Cortex Sclerotii Poriae
3. according to the hydrocephalic Chinese patent medicine of the described treatment of claim 1, wherein the weight proportion of each raw material is:
1.8 parts of 3 parts of Borneolum Syntheticums of Calculus Bovis
18 parts of 18 parts of Radix Angelicae Sinensis of Rhizoma Chuanxiong
9 parts in 18 parts of Rhizoma Gastrodiaes of Rhizoma Acori Graminei
9 parts of 3 parts of Pheretimas of Scolopendra
12 parts on 18 parts of Flos Carthamis of Cortex Sclerotii Poriae
4. according to claim 1, the hydrocephalic Chinese patent medicine of 2 or 3 described treatments, it is characterized in that: said medicament is said powder or capsule or a tablet on the galenic pharmacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98113028A CN1066959C (en) | 1998-11-27 | 1998-11-27 | Medicine for treating hydrocephalus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98113028A CN1066959C (en) | 1998-11-27 | 1998-11-27 | Medicine for treating hydrocephalus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1255337A CN1255337A (en) | 2000-06-07 |
| CN1066959C true CN1066959C (en) | 2001-06-13 |
Family
ID=5222813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98113028A Expired - Fee Related CN1066959C (en) | 1998-11-27 | 1998-11-27 | Medicine for treating hydrocephalus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1066959C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721003B (en) * | 2013-12-29 | 2016-06-01 | 高本安 | One treats the hydrocephalic Chinese medicine preparation of kidney-essence deficiency children's |
| CN104435436A (en) * | 2014-12-19 | 2015-03-25 | 王东宝 | Traditional Chinese medicine preparation for treating hydrocephalus and preparation method of traditional Chinese medicine preparation |
| CN104906528A (en) * | 2015-02-02 | 2015-09-16 | 侯士良 | Traditional Chinese medicine composition used for treating hydrocephalus and application thereof |
| CN104825900A (en) * | 2015-05-30 | 2015-08-12 | 田丽华 | Traditional Chinese medicine for treating hydrocephalus |
| CN110433235A (en) * | 2019-08-26 | 2019-11-12 | 周庆福 | One kind is for treating subdural collection of fluid and various hydrocephalic Chinese medicine compositions |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081897A (en) * | 1993-04-24 | 1994-02-16 | 王筱溥 | " musk naotongsu " |
-
1998
- 1998-11-27 CN CN98113028A patent/CN1066959C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081897A (en) * | 1993-04-24 | 1994-02-16 | 王筱溥 | " musk naotongsu " |
Non-Patent Citations (1)
| Title |
|---|
| 《新中医》1991年第23卷第7期 1991.7.31 宋虎杰通窍活血法治疗脑积水7例报告 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1255337A (en) | 2000-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1686458A (en) | Chinese medicinal composition, its preparation method and use | |
| CN1947757A (en) | Leave of glutinous rehmannia extractive, its prepn. method and use, medicines prepd. with said extractives | |
| CN1883638A (en) | Compound medicine for treating depression and method for preparing same | |
| CN1724002A (en) | Medicinal composition, and its pharmaceutical use | |
| CN1066959C (en) | Medicine for treating hydrocephalus | |
| CN1200723C (en) | White peony and licorice extract and its prepn process | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN1203872C (en) | Medicine for curing chronic colitis | |
| CN1813819A (en) | Hedgehog hydnum fruiting body or hyphostroma and culture extract and formulation and preparing method | |
| CN1833695A (en) | Tonifying speen and tonifying kidney granular and its prepn. method | |
| CN1546014A (en) | Persimmon leaf extract and its preparation and its usage | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1225250C (en) | Efficacious parts compositions for prevention and cure of senile dementia and preparation method | |
| CN1188161C (en) | Medicines for treating cervical vertebra illness | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1305487C (en) | Medicinal composition for treating dysuria due to benign prostatauxe and its preparation method | |
| CN1228079C (en) | Oral medicine for treating child restless syndrome | |
| CN1186026C (en) | Application of hydroxyethyl puerarin in preparation of new medicine for curing cerebrovascular diseases | |
| CN1650895A (en) | Method of extracting medicamout having memory strengthening function from natural plant compound preparation | |
| CN1030275C (en) | Nutrient health composition for middle-aged and old people | |
| CN1290566C (en) | Depression treating medicinal formulation and its preparation process | |
| CN1197611C (en) | Medicine for curing choleithiasis and preparing method thereof | |
| CN1239170C (en) | Chinese patent drug for treating liver cancer | |
| CN1314415C (en) | Skin disease treating Chinese traditional medicine | |
| CN1175828C (en) | Medicinal composition for relieving sexual fatigue and delaying sanility and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |